European Journal of Cancer · 2017 · 225 citations · 27 references
Life SciencesImmunologyOncologyClinical ImmunologyImmunoregulationImmunotherapyCancer ImmunotherapyImmuno-oncology BiomarkersClinical Grading SystemsImmune Therapy Response AssessmentImmunotherapy Response AssessmentImmunotherapy Response BiomarkersPrognostic BiomarkersPrognostic Marker AssessmentPrognostic Score Validation
27
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5